3-bromo-6-chloro-2H-chromene | 122323-08-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-bromo-6-chloro-2H-chromene
• CAS: 122323-08-4
• 化学式: C₉H₆BrClO
• 分子量: 245.503
• InChiKey: VPKMUPXHRCLRHM-UHFFFAOYSA-N

物化性质

• 沸点：
  325.2±42.0 °C(Predicted)
• 密度：
  1.694±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-bromo-6-chloro-2H-chromene 在 lithium aluminium tetrahydride 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 6.0h， 生成 4-Chloro-2-propa-1,2-dienyl-phenol
  参考文献：
  名称：

  A new route to o-allenylphenols

  摘要：

  3 溴苯的阴极还原导致开环反应，生成邻烯基苯基乙酸酯。

  DOI：

  10.1039/c39940001177
• 作为产物：
  描述：

  cis-2,3-dibromoallyl p-chlorophenyl ether 以75%的产率得到
  参考文献：
  名称：

  ARIAMALA, G.;BALASUBRAMANIAN, K. K., TETRAHEDRON, 45,(1989) N 1, C. 309-318

  摘要：

  DOI：

文献信息

• Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
  申请人：Molino F. Bruce

  公开号：US20060052378A1

  公开（公告）日：2006-03-09

  The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R 14 ; with R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 14 defined herein.

  本发明的化合物由以下式中的化学结构表示（I）： 其中： 指定为*的碳原子处于R或S构型；X是从苯并呋喃基、苯并噻吩基、苯并异噻唑基、苯并异噁唑基、吲哚基、吲哚基、异吲哚基、吲哚啉基、苯并咪唑基、苯并噁唑基、苯并噻唑基、苯并三唑基、咪唑并[1,2-a]吡啶基、吡唑并[1,5-a]吡啶基、[1,2,4]三唑并[4,3-a]吡啶基、噻吩并[2,3-b]吡啶基、噻吩并[3,2-b]吡啶基、1H-吡咯并[2,3-b]吡啶基、茚基、茚基、二氢苯并环庚烯基、四氢苯并环庚烯基、二氢苯并噻吩基、二氢苯并呋喃基、吲啉基、萘基、四氢萘基、喹啉基、异喹啉基、4H-喹啉基、9aH-喹啉基、喹唑啉基、喜啉基、邻苯二嗪基、喹啉基、苯并[1,2,3]三嗪基、苯并[1,2,4]三嗪基、2H-香豆素基、4H-香豆素基或者是一个可选地用取代基（1至4个）取代的螺联苯环或螺联杂环的螺联双环碳环或螺联双环杂环； 其中R1、R2、R3、R4、R5、R6、R7、R8和R14在此处定义。
• Thermal behaviour of aryl γ-haloprcpargyl ethers
  作者：G. Ariamala、K.K. Balasubramanian

  DOI：10.1016/0040-4020(89)80058-4

  日期：1989.1

  A systematic study of the behaviour of aryl γ-halopropargyl ethers under thermal condition was undertaken. Aryl γ-bromopropargyl ethers underwent unique transformation in N,N-diethylanillne (215°C, 6 h) giving rise to a mixture of products ,and , whereas, under similar conditions aryl γ-chloropropargyl ethers ulbar|8, afforded 4-chlorochromenes, 9. A remarkable substituent and solvent effect has been

  对芳基γ-卤代炔丙基醚在热条件下的行为进行了系统的研究。芳基γ-溴代炔丙基醚类的N，N-二diethylanillne（215℃，6小时）引起的产物的混合物进行独特变换，并且，反之，在类似条件下芳基γ-chloropropargyl醚ulbar | 8，得到4- chlorochromenes ，9。在这些芳基γ-溴和γ-氯炔丙基醚的热解中观察到了显着的取代基和溶剂作用，从而使这种转化成为合成许多取代的4-溴色烯，4-氯色烯和chroman-4-ones 。相反，芳基γ-碘炔丙基醚的溶液热解得到芳基炔丙基醚。 作为主要产品。
• [EN] MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBANT LA PROTEINE KINASE-2 ACTIVEE PAR LA PROTEINE KINASE ACTIVEE PAR DES AGENTS MITOGENES
  申请人：PHARMACIA CORP

  公开号：WO2004058762A1

  公开（公告）日：2004-07-15

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶2（MK-2）的化合物。描述了使用这些化合物来抑制MK-2，以及预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制剂化合物。还描述了包含本MK-2抑制剂化合物的治疗组合物、药物组合物和试剂盒。
• Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
  申请人：Pharmacia Corporation

  公开号：US20040209897A1

  公开（公告）日：2004-10-21

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF&agr;, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶-2（MK-2）的化合物。本文还描述了使用这些化合物来抑制MK-2并预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制化合物。本文还描述了包含本MK-2抑制化合物的治疗组合物、制药组合物和试剂盒。
• Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin
  申请人：Molino F. Bruce

  公开号：US20060063766A1

  公开（公告）日：2006-03-23

  The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R 14 ; with R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 14 defined herein.

  本发明的化合物由公式（I）中的化学结构表示：其中：指定*的碳原子处于R或S构型中；X是从苯并呋喃基、苯并[b]噻吩基、苯并异噻唑基、苯并异噁唑基、吲哚基、吲哚基、异吲哚基、吲哚咪唑基、苯并噁唑基、苯并噻唑基、苯并三氮唑基、咪唑并[1,2-a]吡啶基、吡唑并[1,5-a]吡啶基、[1,2,4]三唑并[4,3-a]吡啶基、噻吩并[2,3-b]吡啶基、噻吩并[3,2-b]吡啶基、1H-吡咯并[2,3-b]吡啶基、茚基、茚基、二氢苯并环庚基、四氢苯并环庚基、二氢苯并噻吩基、二氢苯并呋喃基、吲哚啉基、萘基、四氢萘基、喹啉基、异喹啉基、4H-喹啉啶基、9aH-喹啉啶基、喹唑啉基、茜素啉基、邻苯二酚基、喹啉并[1,2,3]三唑基、喹啉并[1,2,4]三唑基、2H-香豆素基、4H-香豆素基或者是一个融合的双环碳环或融合的双环杂环，可选地用R14中定义的取代基（1至4个）取代；其中R1、R2、R3、R4、R5、R6、R7、R8和R14在此定义。